Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables - Net: 2016-2024

Historic Receivables - Net for Fortress Biotech (FBIO) over the last 9 years, with Dec 2024 value amounting to $10.2 million.

  • Fortress Biotech's Receivables - Net rose 68.52% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year increase of 68.52%. This contributed to the annual value of $10.2 million for FY2024, which is 32.79% down from last year.
  • Fortress Biotech's Receivables - Net amounted to $10.2 million in FY2024, which was down 32.79% from $15.2 million recorded in FY2023.
  • Over the past 5 years, Fortress Biotech's Receivables - Net peaked at $28.2 million during FY2022, and registered a low of $10.2 million during FY2024.
  • Its 3-year average for Receivables - Net is $17.9 million, with a median of $15.2 million in 2023.
  • As far as peak fluctuations go, Fortress Biotech's Receivables - Net soared by 76.73% in 2020, and later tumbled by 46.04% in 2023.
  • Over the past 5 years, Fortress Biotech's Receivables - Net (Yearly) stood at $23.9 million in 2020, then declined by 3.41% to $23.1 million in 2021, then rose by 22.05% to $28.2 million in 2022, then plummeted by 46.04% to $15.2 million in 2023, then slumped by 32.79% to $10.2 million in 2024.